Abstract
Better understanding of the underlying biology of malignant gliomas is critical for the development of early detection strategies and new therapeutics. This study aimed to define genes associated with survival. We investigated whether genes coupled with a class prediction model could be used to define subgroups of high-grade gliomas in a more objective manner than standard pathology. RNAs from 29 malignant gliomas were analysed using Agilent microarrays. We identified 21 genes whose expression was most strongly and consistently related to patient survival based on univariate proportional hazards models. In six out of 10 genes, changes in gene expression were validated by quantitative real-time PCR. After adjusting for clinical covariates based on a multivariate analysis, we finally obtained a statistical significance level for DDR1 (discoidin domain receptor family, member 1), DYRK3 (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 3) and KSP37 (Ksp37 protein). In independent samples, it was confirmed that DDR1 protein expression was also correlated to the prognosis of glioma patients detected by immunohistochemical staining. Furthermore, we analysed the efficacy of the short interfering RNA (siRNA)-mediated inhibition of DDR1 mRNA synthesis in glioma cell lines. Cell proliferation and invasion were significantly suppressed by siRNA against DDR1. Thus, DDR1 can be a novel molecular target of therapy as well as an important predictive marker for survival in patients with glioma. Our method was effective at classifying high-grade gliomas objectively, and provided a more accurate predictor of prognosis than histological grading.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- ALCAM:
-
activated leukocyte cell adhesion molecule
- cDNA:
-
complementary DNA
- Cy:
-
cyanine
- DDR1:
-
discoidin domain receptor family, member 1
- DYRK3:
-
dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 3
- FBS:
-
fetal bovine serum
- ITGA5:
-
integrin alpha 5
- ITGB2:
-
integrin beta 2
- KSP37:
-
Ksp37 protein
- LDHC:
-
lactate dehydrogenase C
- LOC340371:
-
hypothetical protein LOC340371
- MEM:
-
minimum essential medium
- PBS:
-
phosphate-buffered saline
- SLC2A3:
-
solute carrier family 2 member 3
- SLN:
-
sarcolipin
- s.d.:
-
standard deviation
- siRNA:
-
short interfering RNA
References
Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M et al. (2002). J Natl Cancer Inst 94: 513–521.
Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM et al. (2004). Cancer Res 64: 6503–6510.
Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I et al. (2003). Cancer Res 63: 6613–6625.
Hoelzinger DB, Mariani L, Weis J, Woyke T, Berens TJ, McDonough WS et al. (2005). Neoplasia 7: 7–16.
Hunter SB, Brat DJ, Olson JJ, Von Deimling A, Zhou W, Van Meir EG . (2003). Int J Oncol 23: 857–869.
Karpeh MS, Kelsen DP, Tepper JE . (2001) In: Devita Jr VT (ed) Cancer of the Stomach: Cancer, Principles & Practice of Oncology, 6th edn. Lippincott Williams & Wilkins: Philadelphia, pp 1092–1121.
Khan J, Wei JS, Ringner M, Saal LH, Ladanyi M, Westermann F et al. (2001). Nat Med 7: 673–679.
Kim S, Dougherty ER, Shmulevich I, Hess KR, Hamilton SR, Trent JM et al. (2002). Mol Cancer Ther 1: 1229–1236.
Kleihues P, Cavenee WK . (2000). World Health Organization Classification of Tumours of the Nervous System. WHO/IARC: Lyon, France.
Li K, Zhao S, Karur V, Wojchowski DM . (2002). J Biol Chem 277: 47052–47060.
Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK et al. (2005). Proc Natl Acad Sci USA 102: 5814–5819.
Mischel PS, Cloughesy TF, Nelson SF . (2004). Nat Rev Neurosci 5: 782–792.
Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G et al. (2003). Oncogene 22: 2361–2373.
Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C et al. (2005). Cancer Res 65: 1678–1686.
Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C et al. (2003). Cancer Res 63: 1602–1607.
Ogawa K, Tanaka K, Ishii A, Nakamura Y, Kondo S, Sugamura K et al. (2001). J Immunol 166: 6404–6412.
Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M et al. (2001). Proc Natl Acad Sci USA 98: 15149–15154.
Ram R, Lorente G, Nikolich K, Urfer R, Foehr E, Nagavarapu U . (2006). J Neurooncol 76: 239–248.
Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM et al. (2001). Cancer Res 61: 6885–6891.
Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK et al. (2005). Cancer Res 65: 4051–4058.
Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P et al. (2000). Cancer Res 60: 6617–6622.
Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF et al. (2003). Oncogene 22: 4918–4923.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al. (2003). Proc Natl Acad Sci USA 100: 8418–8423.
Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, Nambiar S et al. (2005). Oncogene 24: 7073–7083.
Stewart LA . (2002). Lancet 359: 1011–1018.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. (2005). N Engl J Med 352: 987–996.
van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW et al. (2002). N Engl J Med 347: 1999–2009.
van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. (2002). Nature 415: 530–536.
van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS et al. (2003). Am J Pathol 163: 1033–1043.
Vogel W . (1999). FASEB J 13: S77–82.
Vogel W, Brakebusch C, Fassler R, Alves F, Ruggiero F, Pawson T . (2000). J Biol Chem 275: 5779–5784.
Weiner HL, Zagzag D . (2000). Cancer Invest 18: 544–554.
Wong KK, Chang YM, Tsang YT, Perlaky L, Su J, Adesina A et al. (2005). Cancer Res 65: 76–84.
Yoshimura T, Matsuyama W, Kamohara H . (2005). Immunol Res 31: 219–230.
Acknowledgements
We are grateful to N Kiyama and F Higuchi for their excellent technical assistance. We thank Dr Rich Simon and Amy Peng for providing the BRB ArrayTools software. The free software was very useful and developed for user-friendly applications. We also thank Tetsutaro Hamano for statistical advices and analysis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yamanaka, R., Arao, T., Yajima, N. et al. Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 25, 5994–6002 (2006). https://doi.org/10.1038/sj.onc.1209585
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209585
Keywords
This article is cited by
-
A network map of discoidin domain receptor 1(DDR1)-mediated signaling in pathological conditions
Journal of Cell Communication and Signaling (2023)
-
Discoidin domain receptor 1 promotes hepatocellular carcinoma progression through modulation of SLC1A5 and the mTORC1 signaling pathway
Cellular Oncology (2022)
-
MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1
Journal of Experimental & Clinical Cancer Research (2019)
-
Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1
Scientific Reports (2019)
-
Discoidin domain receptor 1 (DDR1), a promising biomarker, induces epithelial to mesenchymal transition in renal cancer cells
Tumor Biology (2016)